Last reviewed · How we verify
VIS649
At a glance
| Generic name | VIS649 |
|---|---|
| Sponsor | Visterra, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) (PHASE3)
- First in Human Study to Assess Safety of VIS649 in Healthy Subjects (PHASE1)
- Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (PHASE2, PHASE3)
- Safety and Efficacy Study of VIS649 for IgA Nephropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIS649 CI brief — competitive landscape report
- VIS649 updates RSS · CI watch RSS
- Visterra, Inc. portfolio CI